Combined holmium laser enucleation of the prostate with high-intensity focused ultrasound in treating patients with localized prostate cancer in a prostate with volume > 60 g: Oncological and functional outcomes from single-institution study

Tarek Ajami; Ruben Blachman-Braun; Joao G Porto; Chad R Ritch; Mark L Gonzalgo; Sanoj Punnen; Hemendra N Shah; Dipen J Parekh; Bruno Nahar

doi:10.1016/j.urolonc.2024.04.022

Combined holmium laser enucleation of the prostate with high-intensity focused ultrasound in treating patients with localized prostate cancer in a prostate with volume > 60 g: Oncological and functional outcomes from single-institution study

Urol Oncol. 2024 May 23:S1078-1439(24)00442-3. doi: 10.1016/j.urolonc.2024.04.022. Online ahead of print.

Authors

Tarek Ajami¹, Ruben Blachman-Braun¹, Joao G Porto¹, Chad R Ritch¹, Mark L Gonzalgo¹, Sanoj Punnen¹, Hemendra N Shah¹, Dipen J Parekh¹, Bruno Nahar²

Affiliations

¹ Desai Sethi Urology Institute, University of Miami, Miller School of Medicine, Miami, FL.
² Desai Sethi Urology Institute, University of Miami, Miller School of Medicine, Miami, FL. Electronic address: brunonahar@miami.edu.

PMID: 38789378
DOI: 10.1016/j.urolonc.2024.04.022

Abstract

Objective: To assess the efficacy and safety of combined High-Intensity Focused Ultrasound (HIFU) and Holmium Laser Enucleation of the Prostate (HoLEP) in treating patients with both localized prostate cancer (PCa) and prostate > 60 g.

Methods: All patients who underwent HIFU for treatment of localized PCa were prospectively enrolled in our study. We reviewed records of patients undergoing procedures from January 2016 to January 2023. For patients with prostate sizes > 60 g, HoLEP was offered before HIFU to prevent worsened urinary symptoms post-treatment. Oncological outcomes-prostatic-specific (PSA) kinetics, recurrence rates, treatment failure - and functional results-Sexual Health Inventory for Men (SHIM), International Prostate Symptoms Score (IPSS), and urinary complications were compared between patients undergoing combined HoLEP and HIFU with those underwent HIFU-monotherapy.

Results: Among 100 patients, 74 underwent HIFU-monotherapy and 26 underwent the combined HoLEP and HIFU. The majority had intermediate-risk PCa (67%). Pathologic assessment of HoLEP specimens showed no tumor evidence in 57% of cases. In comparison to the HIFU-only group, the combined group exhibited significantly lower PSA metrics across various intervals, however, no differences were found regarding overall and infield recurrences and treatment failure rates. While the combined treatment initially resulted in higher incontinence rates and shorter catheterization durations (P < 0.001), no significant difference in IPSS was observed during subsequent follow-ups.

Conclusion: HoLEP and HIFU can be safely combined for the treatment of PCa in patients with >60 g prostate volume without compromising early oncological outcomes thereby expanding the therapeutic scope of HIFU in treating patients with localized PCa and large adenomas.

Keywords: Focal therapy; High-intensity focused ultrasound; Holmium laser enucleation of the prostate; Prostate cancer.